Literature DB >> 33546078

Metachronous primary colon and periampullary duodenal cancer: A case report.

Tao Li1, Xinyu Wang1, Chen Chen2, Xiaobin Song2, Jiannan Li1, Zeyun Zhao1, Nan Zhang1,3, Wei Li1, Kai Zhang1, Tongjun Liu1.   

Abstract

RATIONALE: Primary periampullary duodenal cancer accounts for 3% to 17% of periampullary cancers. There are no previous reports of metachronous primary colon and periampullary duodenal cancer. PATIENT CONCERNS: We present a case of primary periampullary duodenal cancer that occurred metachronously after colon cancer. DIAGNOSES: Imaging and endoscopic examinations, serum tumor marker levels, and pathology confirmed metachronous colon and periampullary duodenal cancer, with 14-month interval between the diagnoses of the 2 malignancies. INTERVENTION: The patient received right hemicolectomy combined with mFOLFOX6 chemotherapy for colon cancer and pancreatoduodenectomy for periampullary duodenal cancer. OUTCOMES: The patient has been followed up for 6 years since the pancreatoduodenectomy and shows no signs of recurrence or metastasis. LESSONS: The risk of developing a second malignancy may be associated with the site of the first tumor. Patients with right colon cancer may have particularly high risk of developing small intestinal cancer, including duodenal cancer. Early detection and active surgical treatments can improve prognosis. Long-term regular follow-up is necessary to detect new malignancies occurring after the diagnosis colon cancer.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33546078      PMCID: PMC7837966          DOI: 10.1097/MD.0000000000024378

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  21 in total

Review 1.  Management of ampullary neoplasms: A tailored approach between endoscopy and surgery.

Authors:  Francesca Panzeri; Stefano Crippa; Paola Castelli; Francesca Aleotti; Alessandro Pucci; Stefano Partelli; Giuseppe Zamboni; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 2.  Treatment for superficial non-ampullary duodenal epithelial tumors.

Authors:  Naomi Kakushima; Hideyuki Kanemoto; Masaki Tanaka; Kohei Takizawa; Hiroyuki Ono
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Primary neoplasms of the small intestine.

Authors:  R M Zollinger
Journal:  Am J Surg       Date:  1986-06       Impact factor: 2.565

4.  Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study.

Authors:  Rasmus Dahlin Bojesen; Lene Buhl Riis; Estrid Høgdall; Ole Haagen Nielsen; Tine Jess
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-08       Impact factor: 11.382

5.  Role of needle knife assisted ampullary biopsy in the diagnosis of periampullary carcinoma.

Authors:  Mohd Talha Noor; Kim Vaiphei; Birinder Nagi; Kartar Singh; Rakesh Kochhar
Journal:  World J Gastrointest Endosc       Date:  2011-11-16

Review 6.  Synchronous double primary gastric and endometrial cancer: a case report and literature review.

Authors:  Mingxu Da; Lingzhi Peng; Yongbin Zhang; Jibin Yao; Yaoxing Duan; Yanghui Wen
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

7.  Multiple primary cancers in extracolonic sites with colorectal cancer.

Authors:  Seung-Hyun Lee; Byung-Kwon Ahn; Sung-Uhn Baek
Journal:  Int J Colorectal Dis       Date:  2008-09-17       Impact factor: 2.571

8.  The effect of multiple primary rules on population-based cancer survival.

Authors:  Hannah K Weir; Christopher J Johnson; Trevor D Thompson
Journal:  Cancer Causes Control       Date:  2013-04-05       Impact factor: 2.506

9.  Primary malignant duodenal tumors.

Authors:  R P Kerremans; J Lerut; F M Penninckx
Journal:  Ann Surg       Date:  1979-08       Impact factor: 12.969

10.  Multiple neoplasms, single primaries, and patient survival.

Authors:  Magid H Amer
Journal:  Cancer Manag Res       Date:  2014-03-05       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.